Personalized/Patient-Specific Compounding: The Only Legal Path in 2026
Key Takeaways
- Patient-specific compounding (503A) requires an individual prescription for a named patient — this is the legal standard
- It's the only clearly legal pathway for compounded semaglutide now that the drug is no longer in shortage
- Your provider writes a prescription specifically for you → the pharmacy compounds it specifically for you
- Batch compounding without individual prescriptions is a 503B function — and faces legal challenges post-shortage
- This pathway has existed for decades — it predates the GLP-1 era and applies to hundreds of medications
The phrase "patient-specific compounding" keeps appearing in GLP-1 regulatory discussions. It's not a marketing term — it's a legal standard that determines whether a compounded medication is legitimate. Here's what it means in practice.
How Patient-Specific Compounding Works
- Provider consultation: A licensed healthcare provider evaluates you individually
- Individual prescription: The provider writes a prescription specifically for you — with your name, your dose, your medication
- Pharmacy compounds: A licensed 503A pharmacy receives the prescription and prepares the medication for you specifically
- Dispensed to you: The medication is shipped or picked up — it was made for you, not pulled from a pre-made batch
Why This Matters in 2026
When semaglutide was in shortage, 503B outsourcing facilities could compound it in bulk without individual prescriptions — a legal exception designed to address supply gaps. With the shortage over, that exception is expiring. Patient-specific 503A compounding doesn't rely on shortage status — it's a permanent legal pathway.
| Factor | Patient-Specific (503A) | Bulk (503B) |
|---|---|---|
| Individual Rx needed? | Yes — always | Not during shortage |
| Legal basis post-shortage? | Unchanged — always legal | Restricted |
| Made for a specific patient? | Yes | No — made in advance |
Embody
GLP-1 · LeadCompounded injectable semaglutide. Established program, strong clinical support. Lead anchor provider.
Patient-specific prescriptions through licensed 503A pharmacy.
MadeMed
Inj. SemaCompounded injectable semaglutide. $119/mo or $89/mo on quarterly plan.
Telos Rx
TirzCompounded tirzepatide. First month from $40; ongoing $160-249/mo.
Patient-specific compounding is the gold standard for legal, safe compounded semaglutide in 2026. It requires a real provider consultation, a real individual prescription, and a real licensed pharmacy making your medication specifically for you. If your current provider follows this model, your legal standing is solid regardless of how FDA policy evolves.
GLP-1 Compound Pharmacy Editorial
Independent compounding pharmacy research. 503A/503B analysis, safety verification, regulatory tracking. Not medical advice.